NASDAQ:OTLK

Outlook Therapeutics Stock Predictions

etoro logo Buy OTLK
*Your capital is at risk
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

OTLK Prediction Chart

OTLK Predictions History

Latest community submissions for OTLK.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Feb 9, 2021 $2.99 -95.18% $3.10 V 96.45% 1
Nkolo-Kangkolo Ka Nkolo-Kangkolo Ka @Nkolo-KangkoloKa.203398
Feb 9, 2021 $2.85 -95.40% $3.10 X 91.94% 1
JS JS Pro
Feb 8, 2021 $2.08 -96.86% $3.31 V 62.84% 0
JS JS Pro
Dec 21, 2020 $1.48 -94.97% $1.47 X 99.32% 4
sander7100 yo bro sander7100 yo bro Pro @sander7100yobro.167552
Dec 10, 2020 $1.24 -95.23% $1.30 V 95.38% 0
JS JS Pro
Dec 10, 2020 $1.31 -94.96% $1.30 X 99.23% 3
JS JS Pro
Nov 13, 2020 $1.02 -95.10% $1.04 X 98.08% 1
JS JS Pro
Nov 12, 2020 $0.99 -95.01% $0.99 X 99.84% 6
Jun 10, 2019 $1.48 -96.34% $2.02 V 73.27% 0
joe1234 joe1234 Pro
Jun 10, 2019 $2.00 -95.05% $2.02 V 99.01% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for OTLK with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE